

# Asia Pacific Plasma Protease C1-Inhibitor Market Size study, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist) by Dosage Form (Lyphophlised, Injectables) and Country Forecasts 2022-2032

<https://marketpublishers.com/r/ACC480653F06EN.html>

Date: June 2024

Pages: 200

Price: US\$ 3,218.00 (Single User License)

ID: ACC480653F06EN

## Abstracts

Asia Pacific Plasma Protease C1-Inhibitor Market is valued approximately at USD 787.98 million in 2023 and is anticipated to grow with a healthy growth rate of more than 19.48% over the forecast period 2024-2032. Plasma Protease C1-Inhibitor, also known as C1-INH or C1 esterase inhibitor, is a protein found in the blood that plays a crucial role in regulating the complement system and controlling inflammation. It is a natural inhibitor of several proteases, including C1s and C1r, which are part of the classical pathway of the complement system. By inhibiting these proteases, C1-INH helps to prevent excessive activation of the complement cascade and the generation of inflammatory mediators, thereby maintaining immune homeostasis and preventing tissue damage. The increasing adoption of biotechnology and precision medicine is a key trend supporting the growth of Asia Pacific Plasma Protease C1-Inhibitor Market during the forecast period 2024-2032. Targeted treatments for hereditary angioedema (HAE) and similar disorders are becoming increasingly popular as a result of developments in genetic testing, molecular diagnostics, and tailored therapy. This involves the use of medicines utilizing plasma protease C1 inhibitors that are customized to the unique profiles of each patient, leading to better treatment success and fewer adverse effects.

Asia Pacific region is witnessing significant growth in the Plasma Protease C1-Inhibitor Market, driven by several key factors including the increasing prevalence of Hereditary Angioedema (HAE) across Asia Pacific countries, creating a greater demand for effective treatment such as Plasma Protease C1-Inhibitors. Moreover, improvements in

healthcare infrastructure and accessibility to specialized therapies are expanding the market's reach to a larger patient population. Enhanced awareness and higher diagnosis rates of HAE among healthcare professionals are also contributing to the market growth, resulting to a surge in demand for Plasma Protease C1-Inhibitor products. Furthermore, favorable regulatory policies and approvals, coupled with growing healthcare expenditure and investment in rare disease treatments, are creating a supportive environment for Plasma Protease C1-Inhibitor therapies in the Asia Pacific region. These driving factors collectively leverage various growth prospects for the Plasma Protease C1-Inhibitor Market. However, high price of esoteric testing procedures and stringent regulatory requirements is expected stifle market growth between 2022 and 2032.

The key countries considered for the Asia Pacific Plasma Protease C1-Inhibitor Market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was the largest regional market in terms of revenue because the Chinese government provides treatment and awareness of rare illnesses as their highest priority. The market for C1 inhibitors is likely to be significantly impacted by policies that accelerate orphan drug applications as well as lower costs by increasing patient access to these drugs. Moreover, the growing awareness of Hereditary Angioedema (HAE), coupled with the rising focus on improving domestic healthcare are the further factors that are bolstering the regional market growth at a substantial rate. Whereas, the market in India is expected to rise at the fastest rate over the forecast period.

Major market player included in this report are:

CSL Limited (CSL Behring LLC)

Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)

Pharming Group

Company 4

Company 5

Company 6

Company 7

Company 8

Company 9

Company 10

The detailed segments and sub-segment of the market are explained below:

By Drug Type

C1-inhibitors

Kallikrein Inhibitor  
Selective Bradykinin B2 Receptor Antagonist

By Dosage Form  
Lyphophlised  
Injectables

By Region:  
Asia Pacific  
China  
India  
Japan  
Australia  
South Korea  
RoAPAC

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and country level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market

## Contents

### **CHAPTER 1. ASIA PACIFIC PLASMA PROTEASE C1-INHIBITOR MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 1.1. Research Objective
- 1.2. Market Definition
- 1.3. Research Assumptions
  - 1.3.1. Inclusion & Exclusion
  - 1.3.2. Limitations
  - 1.3.3. Supply Side Analysis
    - 1.3.3.1. Availability
    - 1.3.3.2. Infrastructure
    - 1.3.3.3. Regulatory Environment
    - 1.3.3.4. Market Competition
    - 1.3.3.5. Economic Viability (Consumer's Perspective)
  - 1.3.4. Demand Side Analysis
    - 1.3.4.1. Regulatory frameworks
    - 1.3.4.2. Technological Advancements
    - 1.3.4.3. Environmental Considerations
    - 1.3.4.4. Consumer Awareness & Acceptance
- 1.4. Estimation Methodology
- 1.5. Years Considered for the Study
- 1.6. Currency Conversion Rates

### **CHAPTER 2. EXECUTIVE SUMMARY**

- 2.1. Asia Pacific Plasma Protease C1-Inhibitor Market Size & Forecast (2022- 2032)
- 2.2. Regional Summary
- 2.3. Segmental Summary
  - 2.3.1. By Drug Type
  - 2.3.2. By Dosage Form
- 2.4. Key Trends
- 2.5. Recession Impact
- 2.6. Analyst Recommendation & Conclusion

### **CHAPTER 3. ASIA PACIFIC PLASMA PROTEASE C1-INHIBITOR MARKET DYNAMICS**

- 3.1. Market Drivers
- 3.2. Market Challenges
- 3.3. Market Opportunities

## **CHAPTER 4. ASIA PACIFIC PLASMA PROTEASE C1-INHIBITOR MARKET: INDUSTRY ANALYSIS**

- 4.1. Porter's 5 Force Model
  - 4.1.1. Bargaining Power of Suppliers
  - 4.1.2. Bargaining Power of Buyers
  - 4.1.3. Threat of New Entrants
  - 4.1.4. Threat of Substitutes
  - 4.1.5. Competitive Rivalry
  - 4.1.6. Futuristic Approach to Porter's 5 Force Model
  - 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
  - 4.2.1. Political
  - 4.2.2. Economic
  - 4.2.3. Social
  - 4.2.4. Technological
  - 4.2.5. Environmental
  - 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. ASIA PACIFIC PLASMA PROTEASE C1-INHIBITOR MARKET SIZE & FORECASTS BY DRUG TYPE 2022-2032**

- 5.1. C1-inhibitors
- 5.2. Kallikrein Inhibitor
- 5.3. Selective Bradykinin B2 Receptor Antagonist

## **CHAPTER 6. ASIA PACIFIC PLASMA PROTEASE C1-INHIBITOR MARKET SIZE & FORECASTS BY DOSAGE FORM 2022-2032**

- 6.1. Lyphophlised

## 6.2. Injectables

### **CHAPTER 7. ASIA PACIFIC PLASMA PROTEASE C1-INHIBITOR MARKET SIZE & FORECASTS BY COUNTRY 2022-2032**

#### 7.1. China Plasma Protease C1-Inhibitor Market

7.1.1. Drug Type breakdown size & forecasts, 2022-2032

7.1.2. Dosage Form breakdown size & forecasts, 2022-2032

#### 7.2. India Plasma Protease C1-Inhibitor Market

#### 7.3. Japan Plasma Protease C1-Inhibitor Market

#### 7.4. Australia Plasma Protease C1-Inhibitor Market

#### 7.5. South Korea Plasma Protease C1-Inhibitor Market

#### 7.6. Rest of Asia Pacific Plasma Protease C1-Inhibitor Market

### **CHAPTER 8. COMPETITIVE INTELLIGENCE**

#### 8.1. Key Company SWOT Analysis

8.1.1. Company

8.1.2. Company

8.1.3. Company

#### 8.2. Top Market Strategies

#### 8.3. Company Profiles

8.3.1. CSL Limited (CSL Behring LLC)

8.3.1.1. Key Information

8.3.1.2. Overview

8.3.1.3. Financial (Subject to Data Availability)

8.3.1.4. Product Summary

8.3.1.5. Market Strategies

8.3.2. Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)

8.3.3. Pharming Group

8.3.4. Company

8.3.5. Company

8.3.6. Company

8.3.7. Company

8.3.8. Company

8.3.9. Company

8.3.10. Company

### **CHAPTER 9. RESEARCH PROCESS**

## 9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

## 9.2. Research Attributes

## List Of Tables

### LIST OF TABLES

TABLE 1. Asia Pacific Plasma Protease C1-Inhibitor Market, report scope

TABLE 2. Asia Pacific Plasma Protease C1-Inhibitor Market estimates & forecasts by Country 2022-2032 (USD Million)

TABLE 3. Asia Pacific Plasma Protease C1-Inhibitor Market estimates & forecasts by Drug Type 2022-2032 (USD Million)

TABLE 4. Asia Pacific Plasma Protease C1-Inhibitor Market estimates & forecasts by Dosage Form 2022-2032 (USD Million)

TABLE 5. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, estimates & forecasts, 2022-2032 (USD Million)

TABLE 6. Asia Pacific Plasma Protease C1-Inhibitor Market by country, estimates & forecasts, 2022-2032 (USD Million)

TABLE 7. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, estimates & forecasts, 2022-2032 (USD Million)

TABLE 8. Asia Pacific Plasma Protease C1-Inhibitor Market by country, estimates & forecasts, 2022-2032 (USD Million)

TABLE 9. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, estimates & forecasts, 2022-2032 (USD Million)

TABLE 10. Asia Pacific Plasma Protease C1-Inhibitor Market by country, estimates & forecasts, 2022-2032 (USD Million)

TABLE 11. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, estimates & forecasts, 2022-2032 (USD Million)

TABLE 12. Asia Pacific Plasma Protease C1-Inhibitor Market by country, estimates & forecasts, 2022-2032 (USD Million)

TABLE 13. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, estimates & forecasts, 2022-2032 (USD Million)

TABLE 14. Asia Pacific Plasma Protease C1-Inhibitor Market by country, estimates & forecasts, 2022-2032 (USD Million)

TABLE 15. China Plasma Protease C1-Inhibitor Market estimates & forecasts, 2022-2032 (USD Million)

TABLE 16. China Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 17. China Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 18. India Plasma Protease C1-Inhibitor Market estimates & forecasts, 2022-2032 (USD Million)



TABLE 19. India Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 20. India Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 21. Japan Plasma Protease C1-Inhibitor Market estimates & forecasts, 2022-2032 (USD Million)

TABLE 22. Japan Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 23. Japan Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 24. Australia Plasma Protease C1-Inhibitor Market estimates & forecasts, 2022-2032 (USD Million)

TABLE 25. Australia Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 26. Australia Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 27. South Korea Plasma Protease C1-Inhibitor Market estimates & forecasts, 2022-2032 (USD Million)

TABLE 28. South Korea Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 29. South Korea Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 30.

TABLE 31. RoAPAC Plasma Protease C1-Inhibitor Market estimates & forecasts, 2022-2032 (USD Million)

TABLE 32. RoAPAC Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 33. RoAPAC Plasma Protease C1-Inhibitor Market estimates & forecasts by segment 2022-2032 (USD Million)

TABLE 34. List of secondary sources, used in the study of Asia Pacific Plasma Protease C1-Inhibitor Market.

TABLE 35. List of primary sources, used in the study of Asia Pacific Plasma Protease C1-Inhibitor Market.

TABLE 36. Years considered for the study.

TABLE 37. Exchange rates considered

## List Of Figures

### LIST OF FIGURES

- FIG 1. Asia Pacific Plasma Protease C1-Inhibitor Market, research methodology
- FIG 2. Asia Pacific Plasma Protease C1-Inhibitor Market, market estimation techniques
- FIG 3. Asia Pacific market size estimates & forecast methods.
- FIG 4. Asia Pacific Plasma Protease C1-Inhibitor Market, key trends 2023
- FIG 5. Asia Pacific Plasma Protease C1-Inhibitor Market, growth prospects 2022-2032
- FIG 6. Asia Pacific Plasma Protease C1-Inhibitor Market, porters 5 force model
- FIG 7. Asia Pacific Plasma Protease C1-Inhibitor Market, pestel analysis
- FIG 8. Asia Pacific Plasma Protease C1-Inhibitor Market, value chain analysis
- FIG 9. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, 2022 & 2032 (USD Million)
- FIG 10. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, 2022 & 2032 (USD Million)
- FIG 11. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, 2022 & 2032 (USD Million)
- FIG 12. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, 2022 & 2032 (USD Million)
- FIG 13. Asia Pacific Plasma Protease C1-Inhibitor Market by segment, 2022 & 2032 (USD Million)
- FIG 14. Asia Pacific Plasma Protease C1-Inhibitor Market, Country snapshot 2022 & 2032
- FIG 15. Asia Pacific Plasma Protease C1-Inhibitor Market 2022 & 2032 (USD Million)
- FIG 16. Asia Pacific Plasma Protease C1-Inhibitor Market, company market share analysis (2023)

## I would like to order

Product name: Asia Pacific Plasma Protease C1-Inhibitor Market Size study, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist) by Dosage Form (Lyphophlised, Injectables) and Country Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/ACC480653F06EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ACC480653F06EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970